Regencell Bioscience Holdings (RGC) IPO Opens 26% Higher

Today's IPO for Regencell Bioscience Holdings (NASDAQ: RGC) opened for trading at $12 after pricing 2,300,000 ordinary shares at a public offering price of $9.50 per ordinary share.

Hunter Taubman Fischer & Li LLC is acting as counsel to the Company, and Loeb & Loeb LLP is acting as counsel to Maxim Group LLC in connection with the Offering.

Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on research, development and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. The Company started in Hong Kong in 2014 and completed its first research study using personalized TCM formula in Hong Kong. The Company aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients in Hong Kong first and subsequently to other markets as we deem appropriate.

You May Also Be Interested In

• SpaceX shares gain as lock-up fears ease
• Braveheart Bio raises $439.9M in upsized Nasdaq IPO
• East West Ave Acquisition Corp. raises $100M in Nasdaq IPO